Sinovac Biotech's market cap is currently ―. The company's EPS TTM is $-3.633; its P/E ratio is -1.78; Sinovac Biotech is scheduled to report earnings on April 29, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Jun 22	Dec 21	Jun 21	Dec 20
Income Statement	-
Total Revenue	-	-	-	-	$ 327.45M
Gross Profit	-	-	-	-	$ 283.93M
EBIT	-	-	-	-	$ 198.69M
EBITDA	-	-	-	-	$ 199.95M
Net Income Common Stockholders	-	-	-	-	$ 107.32M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 11.32B	$ 11.85B	$ 13.42B	$ 9.82B	$ 1.18B
Total Assets	$ 14.11B	$ 15.07B	$ 16.75B	$ 12.63B	$ 1.90B
Total Debt	$ 70.31M	$ 81.72M	$ 144.91M	$ 174.58M	$ 136.39M
Net Debt	$ -11.25B	$ -11.76B	$ -13.27B	$ -9.64B	$ -1.04B
Total Liabilities	$ 1.40B	$ 971.93M	$ 2.87B	$ 3.50B	$ 781.20M
Stockholders Equity	$ 8.92B	$ 9.47B	$ 9.33B	$ 5.87B	$ 746.47M
Cash Flow	-
Free Cash Flow	-	-	-	-	$ 423.23M
Operating Cash Flow	-	-	-	-	$ 481.10M
Investing Cash Flow	-	-	-	-	$ -152.15M
Financing Cash Flow	-	-	-	-	$ 541.64M

Currency in USD

Sinovac Biotech Earnings and Revenue History

Income Statement >

Sinovac Biotech Debt to Assets

Balance Sheet >

Sinovac Biotech Cash Flow

Cash Flow >

Sinovac Biotech Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing